Rocket Pharmaceuticals, Inc. RCKT
Biotechnology: Pharmaceutical Preparations · IPO 2015 · data as of November 13, 2026
Rocket Pharmaceuticals, Inc. (RCKT) is a healthcare company listed in the US with a market value of about $257M.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -49%.
About Rocket Pharmaceuticals
Rocket Pharmaceuticals is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2015. It was profitable in 0 of the last 10 years in our data. Its share count rose by 63% over three years (dilution for shareholders).
Score: 0.4 / 5
Checks passed
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$223M | -$259M | -$246M | -$222M | -$169M | -$140M | -$77M | -$75M | -$20M | -$8M |
| Free cash flow | -$190M | -$216M | -$211M | -$186M | -$129M | -$95M | -$88M | -$55M | -$17M | -$6M |
| EPS (diluted) | $-2.01 | $-2.73 | $-2.92 | $-3.26 | $-2.67 | $-2.52 | $-1.58 | $-1.89 | $-2.88 | $-1.11 |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| ROIC | -82.5% | -58.4% | -41.3% | -36.1% | -28.9% | -20.8% | -19.4% | -29.0% | -100.6% | -71.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 11 analysts is $8.82, 283% above the current price; targets range from $4.00 to $15.00; the consensus rating is “Buy”; expected EPS is $-0.12 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Rocket Pharmaceuticals pay a dividend?
Not currently.
Is Rocket Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Rocket Pharmaceuticals scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.